Previous Article |
Table of Contents
| Next Article
Edited by Aaron Klug, Medical Research Council, Cambridge, United
Kingdom, and approved December 19, 2000 (received for review July 3, 2000)
The chemotherapeutic drug Taxol is known to interact within a
specific site on Taxol 1a
[paclitaxel (PTX)] and Taxotere 1b (docetaxel) are
important antitumor agents used clinically in the treatment of
refractory ovarian cancer, small-cell lung cancer, metastatic breast
disease, and other manifestations of the affliction (1). The drugs are
believed to block cell-cycle progression during mitosis by binding to
and stabilizing microtubules (MTs) (2, 3). One functional
taxoid-binding site per tubulin (TB) dimer (4, 5) has been located on
the
Pharmacology
The binding conformation of Taxol in
-tubulin: A model based
on electron crystallographic density
,
,
,
, and
,§
Department of Chemistry, Emory University, Atlanta,
GA 30322;
Life Sciences Division, Lawrence Berkeley
National Laboratory, Berkeley, CA 94720; and
§ Molecular and Cell Biology, University of California,
Berkeley, CA 94720
![]()
Abstract
Top
Abstract
Introduction
Methods
Discussion
Summary and Conclusions
References
-tubulin. Although the general location of the site
has been defined by photoaffinity labeling and electron crystallography, the original data were insufficient to make an absolute determination of the bound conformation. We have now correlated the crystallographic density with analysis of Taxol conformations and have found the unique solution to be a T-shaped Taxol
structure. This T-shaped or butterfly structure is optimized within the
-tubulin site and exhibits functional similarity to a portion of the
B9-B10 loop in the
-tubulin subunit. The model provides structural
rationalization for a sizeable body of Taxol structure-activity
relationship data, including binding affinity, photoaffinity labeling,
and acquired mutation in human cancer cells.
![]()
Introduction
Top
Abstract
Introduction
Methods
Discussion
Summary and Conclusions
References
-subunit (6-11). The recently determined 3.7-Å structure of
the 
-TB-PTX complex (12), obtained by electron crystallography
(EC) of zinc-induced TB sheets, clearly shows the location of the
binding site but lacks the resolution to completely determine the
ligand conformation. Therefore, in the original report, the x-ray
crystal structure of Taxotere (13) served as a PTX surrogate. More
recently, the EC crystal structure of TB has been docked into a 20-Å
map of the MT to provide a high-resolution model of this polymer (14).
The excellent fit indicates the similarity of the TB conformation in
MTs and zinc-induced sheets. In the present work, we integrate the
electron-density map of the refined complex and a three-step modeling
strategy to define the PTX-binding conformation in the EC
structure.

View larger version (10K):
[in a new window]
Scheme 1.
| |
Methods |
|---|
|
|
|---|
Conformational Selection and Fitting. Taxol combines a polar and rigid tetracyclic core with an equally polar set of four flexible side chains, containing 10 single bonds that contribute to the conformational flexibility of the molecule. Here we have explicitly considered 26 PTX conformers derived from x-ray crystal structures and from NMR nuclear Overhauser effect data of PTX and its derivatives (15-24) and a large number of computer-generated conformers. The individual conformers were docked into the experimental density map of the TB-PTX complex. Examples are portrayed in Fig. 1. Most of the conformations leave the terminal C-13 phenyl rings in regions completely devoid of density. Two of these are shown in Fig. 1 a and b. On the other hand, three very similar conformations, two from the solid state (15, 16) and one from solution (24), gave reasonable fits. One of the former was used as a starting point for further refinement of the TB-PTX complex (Fig. 1c).
|
Stepped Optimization. Coordinates used for optimization were obtained by refinement¶ of those placed on deposit at the Brookhaven Protein Data Bank (1TUB.pdb). Results of restricted low-temperature dynamics and force-field optimization were monitored for fit within the experimental density. Details are published as supplemental data on the PNAS web site (www.pnas.org).
Automated Docking. To certify that the T- or butterfly-binding motif is both unique and reproducible, PTX was removed from its protein complex, conformationally altered, and flexibly redocked into the binding pocket by using standard DOCK methodology (ref. 25; http://www.cmpharm.ucsf.edu/kuntz/kuntz.html). Although many partially docked PTX structures were generated, only two conformers were encased by the protein. The lowest energy form is identical in shape and location to that in Fig. 3. The other was scored 45 kcal/mol higher in energy and involves a torsional exchange of C-3' phenyl and C-3' NHCOPh. In this orientation, the side chains fall clearly outside the EC density, ruling out the alternative conformation. No other binding mode within the ligand groove was identified. A second docking experiment with FlexX, a fragment-based flexible docking algorithm (ref. 26; http://cartan.gmd.de/flexx/), generated 200 PTX conformers. T-Taxol was docked twice. The orientation is shown in Figs. 3 and 4a as the lowest energy form. Scoring data are given in the supplementary material.
| |
Discussion |
|---|
|
|
|---|
Analysis of Taxol Conformation.
There have been many speculations as to the bioactive conformation of
PTX complexed with MTs. Initially, the nonpolar conformer, with the C-2
and C-3' phenyl side chains exhibiting hydrophobic collapse (Fig.
2a), was proposed as the
bioactive one (17-19). Shortly thereafter, however, several
laboratories argued in favor of the polar form (20-22) that juxtaposes
the C-2 and C-3' benzamido side chains (Fig. 2b) (27). More
recently, during the processing of this manuscript, a pharmacophore
model (28) and two studies using PTX docked into EC
-TB appeared,
which also favor the polar structure (29, 30). The binding conformation
derived from the present analysis belongs to neither extreme. As
illustrated by Fig. 2c, PTX's bound state in our model is
characterized by the C-2 benzoyl phenyl, nearly equidistant from both
of the phenyl rings emanating from C-3' in T-Taxol. A recent gas-phase
ab initio conformational analysis of the PTX C-13 side chain
led to a similar binding proposal (31), underscoring the notion that
low-energy experimental conformational minima are prime candidates for
protein-bound small molecules (32). The ligand structure corresponds to
one member of the family of low population conformers found by NMR deconvolution analysis in chloroform (24) and DMSO/water
(J.P.S., N. Nevins, J. Jiménez-Barbero, D. Cicero, and J. M. Jansen, unpublished work). With T-Taxol nestled in the EC density of
the computationally refined PTX-TB complex, residue His-229 of the
protein is interposed between the PTX C-3' and C-2 phenyl rings,
preventing their hydrophobic collapse (Figs.
3 and
4a). The same observation with
respect to C-2 has been made in connection with 2-m-azido
baccatin III (33). In association with
-TB, each of PTX's
hydrophobic centers engages in complementary interactions with the
protein (Fig. 4a) rather than self, as in the polar and
nonpolar conformations. This picture predicts that taxoid design and
synthesis based on a hydrophobically collapsed motif are likely to lead
to inactive compounds. The point has been made decisively in one
completely inactive series in which Georg, Himes, and coworkers
tethered the C-3' and C-2 phenyls with several two-atom spacers (34).
|
|
|
Binding-Site Interactions.
In our model, the binding pocket for PTX resides in a deep hydrophobic
cleft near the surface of
-TB, where it interacts with the protein
by means of three potential hydrogen bonds and multiple hydrophobic
contacts. Importantly, the walls of the pocket are composed of several
elements of secondary structure linked by the PTX molecule. Segments of
helices H1, H6, H7, and the loop between H6 and H7 are anchored by
hydrophobic interactions with PTX's 3'-benzamido phenyl, the
3'-phenyl, and the 2-benzoyl phenyl (Fig. 4a). In addition,
the 3'-phenyl enjoys close contacts with
-sheet strands B8 and B10.
The refined site model suggests that a backbone NH of the loop
connecting strands B9 and B10 is hydrogen bonded to 2'-OH. The C-4
acetate is situated above a 10-residue hydrophobic basin [Leu-230,
Ala-233 (H7); Phe-272, Pro-274, CH3 of Thr-276,
Leu-286, Leu-291 (M-loop); Pro-360, Leu-371 (B9-B10 loop); and
CH2 of Ser-374 (B10)], half of which derives
from the N-terminal end of the long meandering loop that connects B7
and H9, the M-loop (14). The C-8 methyl is directed toward the M-loop, putting it in van der Waals contact with two residues near the C-terminal end, Thr-276 and Gln-281. The ligand's O-21 appears to
experience a weak electrostatic interaction with the same loop via
Thr-276 (35). Finally, the model places the taxoid's C-12 methyl in
close proximity to Leu-371 on the B9-B10 loop. Thus, both side chains
and baccatin core of the ligand contribute to the scaffold of
interactions. Fig. 5 depicts
-TB with
its surface represented in terms of hydrophobicity. The empty and
Taxol-occupied binding pocket is presented in brown in Fig. 5
a and b. When the ligand-protein complex surface
is recolored to include the ligand, it is clear that Taxol binding
converts a hydrophobic cleft into a hydrophilic surface (Fig.
5c). The equivalent locus in
-TB is occupied by an
eight-residue insertion in the loop connecting strands B9 and B10
(Thr-361-Leu-368; see Fig. 4b). Population of the
-TB
cleft by Taxol or competitive biomimetics produces protofilaments with
a homogeneous face that conceivably contributes to both the formation
of MTs by lateral polymerization and to MT
stability.
It likewise
suggests the possibility that a properly constituted peptide,
endogenous or synthetic, could operate in like manner in
PTX's absence.
|
Structure-Activity Relationships. The model for the PTX-TB complex presented here is in excellent agreement with important elements of the structure-activity relationship data. First, the bioactivity of PTX is relatively insensitive to chemical manipulation from C-7 to C-10 (37). This section of the molecule is not engaged in binding the protein but is projected outward away from the surface of the macromolecule. Second, evidence has accumulated that the C-2' hydroxyl is critical for biological activity (38, 39) and is a hydrogen bond donor (40). In agreement, a hydrogen bond from C-2' OH to the backbone carbonyl of Arg-369 exists in the model. Third, replacement of phenyl groups with cyclohexyl moieties in the C-13 and C-2 side chains sustains the activity of PTX (41, 42). The location of each of the rings in a generous hydrophobic space is compliant. Fourth, extension of the C-4 acetate by longer alkyl chains without loss of activity (43) is explained by the location of the C-4 methyl at the top of a deep hydrophobic cleft. Fifth, meta substitution in the phenyl of the C-2 side-chain enhances activity, whereas para substitution reduces it (44). The hydrophobic subsite housing this phenyl moiety is relatively tight on three sides of the ring but open at one of the meta positions. The elegant deduction by Horwitz, Kingston, and colleagues that appropriate m-substitution permits the elimination of the C-13 side chain without sacrificing potency or efficacy amplifies the point (33). Confirming the structural aspects of their work, our model positions the carboxylate of Asp-226 directly above the central cationic nitrogen of the azide in 2-m-azido baccatin. Sixth, C-6 nor-Taxol derivatives drop activity by 10-20 times (45, 46). Contraction of the C-ring from six members to five pulls the oxetane ring away from Thr-276 and reduces the effectiveness of the O-21/HN-Thr interaction.
Acquired Resistance.
PTX- and epothilone-resistant human ovarian cancer cell lines have been
isolated by Giannakakou et al. and shown to express mutant
-TB with diminished capacity for TB polymerization by the drugs (47,
48). The acquired mutations are Phe-270
Val, Ala-364
Thr,
Thr-274
Ile, and Arg-282
Gln [corresponding to positions 272, Ser-374, 276, and 284 in the structure-based sequence alignment of
-
and
-TB] (12)].** The first two
residues, conferring PTX resistance, line the floor of the deep
hydrophobic pocket surrounding the PTX ligand. In the model of Fig.
4a, Phe-272 resides at one end of
-sheet strand B7 in van der Waals contact with
the methyl group of PTX's C-4 acetate. Ser-374, although not in direct
contact with the ligand, is part of a larger hydrophobic cluster that
includes Ala-273 and Phe-272. Its replacement by threonine can be
viewed as causing a reorganization of the cluster with concomitant
adjustment in the position of Phe-272. In this interpretation, both
mutations modify the character of the floor of the pocket in a similar
manner to effectively block PTX binding. A smaller taxoid surrogate
might well escape these changes in protein sequence and stimulate other mutations, as appears to be the case for epothilone. The third and
fourth mutations, affording epothilone resistance, are found on the
M-loop contiguous with the PTX-binding site (Fig. 4a). They
cause resistance to both PTX and epothilone-driven TB polymerization. From a structural point of view, Thr-276
Ile will influence any hydrogen bond between O-21 and threonine, a phenomenon consistent with
the resistance shown by a carcinoma subline expressing this
-TB
mutant (48). The local electrostatic reorganization does not, however,
capture what must be a more subtle effect. Although it has been
generally believed that the taxane oxetane ring is "absolutely
required" for activity, our recent analysis suggests this not to be
the case. Both a minireceptor treatment and the complex of Fig.
4a were used to predict that the oxetane ring could be
replaced, among others, with a cyclopropane ring without loss in
activity (35). The prediction has been borne out in the Taxotere series
in the work of Dubois et al. (49). Given the uncertainties
in the conformation of the M-loop, our model does not provide a
specific rationale for the Arg-284
Gln substitution apart from
proximity. However, an interesting proposal regarding the disruption of
a hydrogen-bonding network mediated by water molecules has been
advanced (48).
Photoaffinity Labeling.
Photoaffinity-labeling studies distributing photoactive moieties at
distant atoms around PTX (i.e., groups at C-2, C-7, and C-3') have
successfully identified specific residues in the
-TB dimer in close
proximity to the binding pocket. Thus,
[3H]2-(m-aziodbenzoyl) PTX (AzBo-PTX)
photolabels residues 217-231 on and adjacent to helix H7 in
-TB
(10). Providing perfect consistency, the model nestles the C-2 OCO-Ph
ring in a hydrophobic subsite composed of Leu-217, Leu-219, a
CH2 of Asp-226, and His-229 (Fig. 4a).
A second probe, [3H]3'-(p-azidobenzamido) PTX
(AzBa-PTX), competes with PTX binding and labels the N-terminal 31 amino acids of
-TB (6-8). In complete accord, the binding model of
Fig. 4a juxtaposes the phenyl ring of C-3' NHCO-Ph and the
isopropyl group of Val-23 on helix H1. Additionally, the same ring
enjoys short contacts with methylene groups (CH2)
of Lys-19, Glu-22, and Asp-26. Most recently, a compound that
stabilizes MTs in the presence of GTP but does not promote TB
polymerization, [3H]7-(benzoyldihydro-cinnamoyl) PTX
(BzDC-PTX), has been shown to crosslink to
Arg-284 (29). This M-loop
residue is the same amino acid that arises from one of the
epothilone-resistant cell lines discussed above. Flexible docking of
the BzDc-PTX label in the ligand pocket sketched in Fig. 4a
effectively superimposes the baccatin core with that of PTX while
siting the C-7 benzophenone end-group near
Arg-284, as deduced by
Ojima, Horwitz, and coworkers (29). However, the intrusive C-7 side
chain has the potential to induce an unnatural M-loop conformation.
Thus, our docked BzDC-PTX not only accounts for the labeling of Arg-284
but also suggests a reason for the failure of the photolabel to promote
TB polymerization.
Comparison with Other Models.
Three recent reports have used the 3.7-Å resolution EC coordinates of

-TB to derive a protein-bound conformation for either PTX or
epothilone (29, 30, 48). It is important to recall that, whereas the
actual TB sheets examined by EC were stabilized by PTX, the deposited
protein coordinates contain the single-crystal coordinates for Taxotere
in place of the actual ligand (12) [Brookhaven Protein Data Bank
(1TUB.pdb)]. All three studies began the PTX-TB model building with
the isolated small molecule crystal structure coordinates of either
Taxotere or PTX as the starting point, and each ended with essentially
the same conformation. By contrast, the PTX model portrayed by Fig.
4a was derived by fitting numerous conformations followed by
a treatment that remains fully faithful to the EC density of both the
protein and the ligand. Of particular note is the Bane, Kingston, and
Schaefer model (30) derived from a combination of solid-state
rotational echo double resonance (REDOR) NMR and fluorescence
spectroscopy [fluorescence resonance energy transfer (FRET)]. REDOR,
performed on labeled and MT-bound PTX, is a conformational determinant
permitting measurement of the distance between 19F at the
para-position of the C-2 benzoyl substituent and 13C at the
3'-amide carbonyl and the C-3' methine carbons. The values of 9.8 ± 0.5 Å and 10.3 ± 0.5 Å, respectively, led to the choice of
the hydrophobically collapsed polar conformation b in Fig. 2
(rcalc 9.6 and 10.4 Å, respectively). In good
agreement with this measurement, T-Taxol (Fig. 2c) sustains
the corresponding distances at 9.1 and 9.9 Å, respectively.
Consequently, both structures are viable REDOR candidates, although the
intervention of
His-229 between the C-2 and C-13 PTX side chains
(Figs. 3 and 4a) favors the T-form in the pictured binding
mode. FRET, on the other hand, is a ligand orientation probe that
depends on the incorporation of both colchicine (COL) and PTX in
-TB. To fit the FRET-derived COL-to-PTX distances in the context of
the collapsed conformer b, the data were interpreted in
terms of an alternative binding mode in which PTX is rotated 180° in
the binding pocket relative to the present model. Two factors argue
against this binding orientation. First, the polar form in this locus
matches the ligand density much less well than that shown in Fig. 1
a and b. Second, the requirement that COL and PTX
must simultaneously bind to
-TB to derive the PTX-binding mode adds
a new variable to the problem. The two antimitotic drugs influence the
polymerization of TB in a qualitatively different manner, one
destabilizing, the other stabilizing MTs, respectively. Consequently,
there is a reasonable possibility that the altered placement of PTX in
TB doped by COL results from reorganization of the binding site in the
presence of the second drug. As a result, we favor the PTX-only
solution in the refined TB coordinates as shown in Figs. 3 and
4a.
| |
Summary and Conclusions |
|---|
|
|
|---|
A model of the bioactive conformation of PTX in its
-TB-binding
site depicted in Figs. 3 and 4a has been constructed by
making maximum use of empirical information and refinement of the EC structure. In short, two dozen conformers of PTX derived from various
structural studies were fitted into the partial EC density associated
with the ligand in
-TB. One of the best solutions was optimized in
the binding site by applying computational tools in a way that kept the
evolving model fully consistent with the EC density of the protein
complex. The final construct, Figs. 3 and 4a, portrays a
T-shaped or butterfly Taxol conformation operating as a center of
organization for a diversity of secondary structures. Unlike the
commonly proposed polar and nonpolar conformations of the drug, which
experience intramolecular hydrophobic collapse, T-PTX opens up to
permit intermolecular hydrophobic association as seen for the
irregularly stacked C-3' benzamido, His-229, and C-2 benzoyl moieties.
The ligand-protein construct rationalizes a range of
structure-activity data involving synthetic substitution at all parts
of the PTX molecule. It addresses the issue of drug resistance for
several acquired TB mutants in human cancer cells. The new model is in
complete harmony with three photoaffinity-labeling studies focused on
-TB. By comparing the nearly identical
and
subunits of the

-TB dimer, we note that PTX in
-TB appears to serve a purpose
similar to an extended loop in the same location in
-TB. The two
centers can be viewed as acting in tandem to promote lateral
aggregation of TB protofilaments to give mature MTs. Finally, we review
the proposals for PTX conformation at the ligand-binding site and argue
that the present model incorporates numerous advantages that should
prove useful in evaluating and predicting the behavior of taxanes and
taxane-mimetic drugs. We also anticipate that the strategy of combining
diversity-rich, small-molecule, empirical conformational analysis with
3-4 Å resolution electron crystallography will assist the
identification of ligand conformation where partial EC density alone is
insufficient to reconcile ambiguities.
| |
Acknowledgements |
|---|
We are grateful to Dr. Qi Gao (Bristol-Myers Squibb) for providing unpublished x-ray crystal coordinates of several PTX analogs and to Prof. Dennis Liotta (Department of Chemistry, Emory University) for encouragement and support. Prof. Gunda Georg (Department of Medicinal Chemistry, University of Kansas) generously provided access to unpublished results. Support for part of this work was received from the National Institutes of Health and the Department of Energy.
| |
Abbreviations |
|---|
MT, microtubule; TB, tubulin; EC, electron crystallography; PTX, paclitaxel.
| |
Footnotes |
|---|
* To whom reprint requests should be addressed. E-mail: snyder{at}euch4e.chem.emory.edu.
This paper was submitted directly (Track II) to the PNAS office.
¶
The structure of the 
-tubulin dimer
refined to 3.5 Å was obtained by using simulated annealing torsion
angle refinement and phase information from experimental images;
R factor 0.23 and free R factor 0.30; J. Lowe., T. Li, K.H.D., and E.N., unpublished data.
A protofilament consists of a longitudinal
head-to-tail stacking of 
-tubulin dimers. These extended and
observable macrostructures are capable of assembling laterally to give
cylindrical MTs; see ref. 36.
**
The EC structure determination used wild-type pig-brain
tubulin with
-Ser. Formally, the
-Ala-364
Thr mutation is
-Ser-364
Thr here.
| |
References |
|---|
|
|
|---|
| 1. | Holmes, F. A. , Kudelka, A. P. , Kavanagh, J. J. , Huber, M. H. , Ajani, J. A. & Valero, V. (1995) in Taxane Anticancer Agents, eds. Georg, G. I., Chen, T. T., Ojima, I. & Vyas, D. M. (Am. Chem. Soc., Washington, DC), ACS Symposium Series 583, p. 31. |
| 2. | Jordon, M. A. & Wilson, L. (1995) in Taxane Anticancer Agents, eds. Georg, G. I., Chen, T. T., Ojima, I. & Vyas, D. M. (Am. Chem. Soc., Washington, DC), ACS Symposium Series 583, pp. 138-153. |
| 3. | Nicolaou, K. C. , Dai, W.-M. & Guy, R. K. (1994) Angew. Chem. Int. Ed. Engl. 33, 15-44. |
| 4. | Parness, J. & Horwitz, S. B. (1981) J. Cell Biol. 91, 479-587. |
| 5. | Diaz, J. F. & Andreu, J. M. (1993) Biochemistry 32, 2747-2755. |
| 6. | Rao, S. , Horwitz, S. B. & Ringel, I. (1992) J. Natl. Cancer Inst. 84, 785-788. |
| 7. | Rao, S. , Krauss, N. E. , Heerding, J. M. , Swindell, C. S. , Ringel, I. , Orr, G. A. & Horwitz, S. B. (1994) J. Biol. Chem. 269, 3132-3134. |
| 8. | Dasagupta, D. , Park, H. , Harriman, G. C. B. , Georg, G. I. & Himes, R. (1994) J. Med. Chem. 37, 2976-2980. |
| 9. | Combeau, C. , Commerçon, A. , Mioskowski, C. , Rousseau, B. , Aubert, F. & Goeldner, M. (1994) Biochemistry 33, 6676-6683. |
| 10. | Rao, S. , Orr, G. A. , Chaudhary, A. G. , Kingston, D. G. I. & Horwitz, S. B. (1995) J. Biol. Chem. 270, 20235-20238. |
| 11. | Loeb, C. , Combeau, C. , Shret-Sabatier, L. , Breton-Gilet, A. , Faucher, D. , Rousseau, B. , Commerçon, A. & Goeldner, M. (1997) Biochemistry 36, 3820-3825. |
| 12. | Nogales, E. , Wolf, S. G. & Downing, K. H. (1998) Nature (London) 391, 199-202. |
| 13. | Guéritte-Voegelein, F. , Guenard, D. , Mangatal, L. , Potier, P. , Guilhem, J. & Cesario, M. (1990) Acta Crystallogr. C 46, 781-784. |
| 14. | Nogales, E. , Whittaker, M. , Milligan, R. A. & Downing, K. H. (1999) Cell 96, 79-88. |
| 15. | Gao, Q. , Wei, J.-M. & Chen, S.-H. (1995) Pharm. Res. 12, 337-341. |
| 16. | Gao, Q. & Chen, S.-H. (1996) Tetrahedron Lett. 37, 3425-3428. |
| 17. | Dubois, J. , Guénard, D. , Guéritte-Voegelein, F. , Guedira, N. , Potier, P. , Gillet, B. & Beloeil, J.-C. (1993) Tetrahedron 49, 6533-6544. |
| 18. | Williams, H. J. , Scott, A. I. , Dieden, R. A. , Swindell, C. S. , Chirlian, L. E. , Francl, M. M. , Heerding, J. M. & Krauss, N. E. (1993) Tetrahedron 49, 6545-6560. |
| 19. | Cachau, R. E. , Gussio, R. , Beutler, J. A. , Chmurny, G. N. , Hilton, B. D. , Muschik, G. M. & Erickson, J. W. (1994) Supercomput. Appl. High Perform. Comput. 6, 24-34. |
| 20. | Vander Velde, D. G. , Georg, G. I. , Grunewald, G. L. , Gunn, C. W. & Mitscher, L. A. (1993) J. Am. Chem. Soc. 113, 11650-11651. |
| 21. | Paloma, L. G. , Guy, R. K. , Wrasidlo, W. & Nicolaou, K. C. (1994) Chem. Biol. 1, 107-112. |
| 22. | Ojima, I. , Kuduk, S. D. , Chakravarty, S. , Ourevitch, M. & Bégue, J.-P. (1997) J. Am. Chem. Soc. 119, 5519-5527. |
| 23. | Jiménez-Barbero, J. , Souto, A. A. , Abal, M. , Barasoain, I. , Evangelio, J. A. , Acuña, A. U. , Andreu, J. M. & Amat-Guerri, F. (1998) Biorg. Med. Chem. 6, 1857-1863. |
| 24. | Snyder, J. P. , Nevins, N. , Cicero, D. O. & Jansen, J. J. (2000) J. Am. Chem. Soc. 172, 724-725. |
| 25. | Ewing, T. J. A. & Kuntz, E. D. (1997) J. Comp. Chem. 18, 1175-1189. |
| 26. | Rarey, M. , Kramer, B. , Lengauer, T. & Klebe, G. (1996) J. Mol. Biol. 261, 470-489. |
| 27. | Mastropaolo, D. , Camerman, A. , Luo, Y. , Brayer, G. D. & Camerman, N. (1995) Proc. Natl. Acad. Sci. USA 92, 6920-6924. |
| 28. | Ojima, I. , Chakravarty, S. , Inoue, T. , Lin, L. , He, L. , Horwitz, S. B. , Kuduk, S. D. & Danishefsky, S. J. (1999) Proc. Natl. Acad. Sci. USA 96, 4256-4261. |
| 29. | Rao, S. , He, L. , Chakravarty, S. , Ojima, I. , Orr, G. A. & Horwitz, S. B. (1999) J. Biol. Chem. 274, 37990-37994. |
| 30. | Li, Y. , Poliks, B. , Cegelski, L. , Poliks, M. , Gryczynski, Z. , Piszczek, G. , Jagtap, P. G. , Studelska, D. R. , Kingston, D. G. I. , Schaefer, J. & Bane, S. (2000) Biochemistry 39, 281-291. |
| 31. | Milanesio, M. , Ugliengo, P. , Viterbo, D. & Appendino, G. (1999) J. Med. Chem. 42, 291-299. |
| 32. | Klebe, G. (1995) Perspect. Drug Discovery Des. 3, 85-105. |
| 33. | He, L. , Jagtap, P. G. , Kingston, D. G. I. , Shen, H.-J. , Orr, G. A. & Horwitz, S. B. (2000) Biochemistry 39, 3972-3978. |
| 34. | Boge, T. C. , Wu, Z.-J. , Himes, R. H. , Vander Velde, D. G. & Georg, G. I. (1999) Biorg. Med. Chem. Lett. 9, 3047-3052. |
| 35. | Wang, M. , Cornett, B. , Nettles, J. , Liotta, D. C. & Snyder, J. P. (2000) J. Org. Chem. 65, 1059-1068. |
| 36. | Garret, R. H. & Grisham, C. M. (1999) Biochemistry (Sanders College Pub., New York), pp. 534-535. |
| 37. | Kingston, D. G. I. (1995) in Taxane Anticancer Agents, eds. Georg, G. I., Chen, T. T., Ojima, I. & Vyas, D. M. (Am. Chem. Soc., Washington, DC), ACS Symposium Series 583, pp. 203-216. |
| 38. | Guéritte-Voegelein, F. , Guénard, D. , Lavell, F. , LeGoff, M.-T. , Mangatal, L. & Potier, P. (1991) J. Med. Chem. 34, 992-998. |
| 39. | Swindell, C. S. , Krauss, N. E. , Horwitz, S. B. & Ringel, I. (1991) J. Med. Chem. 34, 1176-1184. |
| 40. | Williams, H. J. , Moyna, G. , Scott, A. I. , Swindell, C. S. , Chirlian, L. E. , Heerding, J. M. & Williams, D. K. (1996) J. Med. Chem. 39, 1555-1559. |
| 41. | Ojima, I. , Duclos, O. , Zucco, M. , Bissery, M.-C. , Combeau, C. , Vrignaud, P. , Riou, J. F. & Lavelle, F. (1994) J. Med. Chem. 37, 2602-2608. |
| 42. | Boge, T. C. , Himes, R. H. , Vander Velde, D. G. & Georg, G. I. (1994) J. Med. Chem. 37, 3337-3343. |
| 43. | Chen, S.-H. , Wei, J.-M. , Long, B. H. , Fairchild, C. A. , Carboni, J. , Mamber, W. W. , Rose, W. C. , Johnston, K. , Casazza, A. M. , Kadow, J. F. , et al. (1995) Bioorg. Med. Chem. Lett. 5, 2741-2746. |
| 44. | Chaudhary, A. G. , Gharpure, M. M. , Rimoldi, J. M. , Chordia, M. D. , Gunatilaka, A. A. L. , Kingston, D. G. I. , Grover, S. , Lin, C. & Hamel, E. (1994) J. Am. Chem. Soc. 116, 4097-4098. |
| 45. | Wender, P. A. , Lee, D. & Lal, T. K. (1997) Bioorg. Med. Chem. Lett. 7, 1941-1944. |
| 46. | Liang, X. , Kingston, D. G. I. , Long, B. H. , Fairchild, C. A. & Johnston, K. A. (1997) Tetrahedron 53, 3441-3456. |
| 47. | Giannakakou, P. , Sackett, D. L. , Kang, Y.-K. , Shan, Z. , Buters, J. T. M. , Fojo, T. & Poruchynsky, M. S. (1997) J. Biol. Chem. 272, 17118-17125. |
| 48. | Giannakakou, P. , Gussio, R. , Nogales, E. , Downing, K. H. , Zaharevitz, D. , Bollbuck, B. , Poy, G. , Sackett, D. , Nicolaou, K. C. & Fojo, T. (2000) Proc. Natl. Acad. Sci. USA 97, 2904-2909. (First Published February 25, 2000; 10.1073/pnas.040546297) |
| 49. | Dubois, J. , Thoret, S. , Guéritte, F. & Guénard, D. (2000) Tetrahedron Lett. 41, 3331-3334. |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
C. Ma, C. Li, L. Ganesan, J. Oak, S. Tsai, D. Sept, and N. S. Morrissette Mutations in {alpha}-Tubulin Confer Dinitroaniline Resistance at a Cost to Microtubule Function Mol. Biol. Cell, December 1, 2007; 18(12): 4711 - 4720. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Vandermoere, I. E. Yazidi-Belkoura, Y. Demont, C. Slomianny, J. Antol, J. Lemoine, and H. Hondermarck Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt Mol. Cell. Proteomics, January 1, 2007; 6(1): 114 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Sordet, A. Goldman, and Y. Pommier Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes Mol. Cancer Ther., December 1, 2006; 5(12): 3139 - 3144. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hari, F. Loganzo, T. Annable, X. Tan, S. Musto, D. B. Morilla, J. H. Nettles, J. P. Snyder, and L. M. Greenberger Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of {beta}-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther., February 1, 2006; 5(2): 270 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Marchand, S. Antony, K. W. Kohn, M. Cushman, A. Ioanoviciu, B. L. Staker, A. B. Burgin, L. Stewart, and Y. Pommier A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther., February 1, 2006; 5(2): 287 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Fishman, C. R. Garrett, G. R. Simon, A. A. Chiappori, R. M. Lush, W. R. Dinwoodie, J. J. Mahany, A. M. Dellaportas, A. Cantor, A. Gollerki, et al. Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies Clin. Cancer Res., January 15, 2006; 12(2): 523 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. George, T. Chen, and C. C. Taylor Src Tyrosine Kinase and Multidrug Resistance Protein-1 Inhibitions Act Independently but Cooperatively to Restore Paclitaxel Sensitivity to Paclitaxel-Resistant Ovarian Cancer Cells Cancer Res., November 15, 2005; 65(22): 10381 - 10388. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Diaz, I. Barasoain, A. A. Souto, F. Amat-Guerri, and J. M. Andreu Macromolecular Accessibility of Fluorescent Taxoids Bound at a Paclitaxel Binding Site in the Microtubule Surface J. Biol. Chem., February 4, 2005; 280(5): 3928 - 3937. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Mironov, M. V. Ivannikov, and M. Johansson [Ca2+]i Signaling between Mitochondria and Endoplasmic Reticulum in Neurons Is Regulated by Microtubules: FROM MITOCHONDRIAL PERMEABILITY TRANSITION PORE TO Ca2+-INDUCED Ca2+ RELEASE J. Biol. Chem., January 7, 2005; 280(1): 715 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, A. O'Brate, A. Zelnak, and P. Giannakakou Survivin Deregulation in {beta}-Tubulin Mutant Ovarian Cancer Cells Underlies Their Compromised Mitotic Response to Taxol Cancer Res., December 1, 2004; 64(23): 8708 - 8714. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Nettles, H. Li, B. Cornett, J. M. Krahn, J. P. Snyder, and K. H. Downing The Binding Mode of Epothilone A on {alpha},{beta}-Tubulin by Electron Crystallography Science, August 6, 2004; 305(5685): 866 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ganesh, R. C. Guza, S. Bane, R. Ravindra, N. Shanker, A. S. Lakdawala, J. P. Snyder, and D. G. I. Kingston The bioactive Taxol conformation on {beta}-tubulin: Experimental evidence from highly active constrained analogs PNAS, July 6, 2004; 101(27): 10006 - 10011. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Morrissette, A. Mitra, D. Sept, and L. D. Sibley Dinitroanilines Bind {alpha}-Tubulin to Disrupt Microtubules Mol. Biol. Cell, April 1, 2004; 15(4): 1960 - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Gupta Jr., C. J. Bode, G. I. Georg, and R. H. Himes Understanding tubulin-Taxol interactions: Mutations that impart Taxol binding to yeast tubulin PNAS, May 27, 2003; 100(11): 6394 - 6397. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Diaz, I. Barasoain, and J. M. Andreu Fast Kinetics of Taxol Binding to Microtubules. EFFECTS OF SOLUTION VARIABLES AND MICROTUBULE-ASSOCIATED PROTEINS J. Biol. Chem., February 28, 2003; 278(10): 8407 - 8419. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, K. Gupta, J. Yao, K. Ye, D. Panda, P. Giannakakou, and H. C. Joshi Paclitaxel-resistant Human Ovarian Cancer Cells Undergo c-Jun NH2-terminal Kinase-mediated Apoptosis in Response to Noscapine J. Biol. Chem., October 11, 2002; 277(42): 39777 - 39785. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sale, R. Sung, P. Shen, K. Yu, Y. Wang, G. E. Duran, J.-H. Kim, T. Fojo, P. J. Oefner, and B. I. Sikic Conservation of the Class I {beta}-Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers Mol. Cancer Ther., January 1, 2002; 1(3): 215 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. He, C.-P. Huang Yang, and S. B. Horwitz Mutations in {beta}-Tubulin Map to Domains Involved in Regulation of Microtubule Stability in Epothilone- resistant Cell Lines Mol. Cancer Ther., November 1, 2001; 1(1): 3 - 10. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||